Biodesix to Report Q4 and Full Year 2025 Results

Biotech firm to announce financial performance on February 26, 2026

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Biodesix, Inc., a Nasdaq-listed biotech company based in Louisville, Colorado, announced that it will report its fourth quarter and full year 2025 financial results on February 26, 2026.

Why it matters

As a publicly traded company, Biodesix's quarterly and annual financial performance is closely watched by investors, analysts, and the broader biotech industry. The upcoming report will provide insights into the company's operational and financial health.

The details

Biodesix, which develops diagnostic tests for lung cancer and other diseases, will release its Q4 and full year 2025 results before the market opens on February 26, 2026. The company will also host a conference call and webcast to discuss the financial results and provide a business update.

  • Biodesix will report Q4 and full year 2025 financial results on February 26, 2026.

The players

Biodesix, Inc.

A Nasdaq-listed biotech company that develops diagnostic tests for lung cancer and other diseases, headquartered in Louisville, Colorado.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching Biodesix's upcoming financial report to assess the company's performance and outlook.

The takeaway

Biodesix's Q4 and full year 2025 financial results will provide important insights into the company's operational and financial health as a publicly traded biotech firm.